Global Somatostatin Analogs Market- Industry Analysis and forecast 2019 – 2027: By Type, Treatment, and Region.

Global Somatostatin Analogs Market- Industry Analysis and forecast 2019 – 2027: By Type, Treatment, and Region.

Market Scenario

Global Somatostatin Analogs Market size was valued at US$ XX Bn. in 2019 and the total revenue is expected to grow at a CAGR of 7.3% from 2020 to 2027, reaching nearly US$ XX Bn.   Global Somatostatin Analogs Market   The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of Market leaders, Market followers, and Market disrupters in the report, and the same is reflected in our analysis. Definition: Somatostatin Analogs are the artificial version of Somatostatin that helps control the excessive secretion of hormones, especially the growth hormone and serotonin in the human body. It is commonly used to treat Neuroendocrine Tumors (NETs) and Acromegaly, a rare hormonal disorder, and other such hormonal disorders. Market Dynamics: An increase in the R&D activities in the Somatostatin analogs market is having a positive impact on market growth. A number of studies are being conducted for further research and advancement in the already existing drug molecules. The number of patients diagnosed with Neuroendocrine Tumors (NETs) is increasing each year. This creates a demand to develop improved treatments ultimately resulting in the market growth. World Alliance of Pituitary Organizations (WAPO) has launched a global awareness campaign to increase awareness about Acromegaly and the role of Somatostatin analogs in its treatment. The participation of some major market players gives a further boost to the market. Market Segmentation: The report covers the segments in the Somatostatin Analogs Market such as type and treatment. Based on type, the market size of Octreotide was valued at USD 5.7 Billion in 2019 and is expected to grow at a CAGR of XX% over the forecast period. It was the first and foremost type of Somatostatin analog and is mostly used to treat hormonal disorders. Pasireotide market is anticipated to be the fastest-growing given the fact that awareness regarding Cushing’s syndrome is increasing and hence is the treatment. Region-wise Analysis: North America Somatostatin Analogs Market was valued at US$ XX Mn. in 2019 and is expected to reach a value of US$ XX Mn. by 2027, with a CAGR of XX% during the forecast period. The region will retain its market dominance in the future because of the increased awareness and expenditure on healthcare. The emergence of new companies and the development of improved drugs have also contributed to the market growth in North America. Country-wise Analysis: The rise in spending for healthcare and many new cases registered by the US, Canada, and many Southeast Asian countries has led to an increase in the demand for the Somatostatin Analogs market. The Market in the APAC is projected to register comparatively faster growth in terms of revenue in the future. Competitive Landscape: The competitive landscape section in the Somatostatin Analogs Market offers a deep dive into the profiles of the leading players operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects of the companies having a stronghold in the Somatostatin Analogs Market. In 2014, Pasireotide experienced the highest sales for treating acromegaly. Now it is under phase II clinical trials for advanced/metastatic hepatocellular carcinoma. The objective of the report is to present a comprehensive analysis of the Global Somatostatin Analogs Market including all the stakeholders of the industry. The past and current status of the industry with the forecasted Market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes Market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Somatostatin Analogs Market dynamics, structure by analyzing the Market segments and projects the Global Somatostatin Analogs Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Somatostatin Analogs Market make the report investor’s guide.

Scope of the Global Somatostatin Analogs Market

Global Somatostatin Analogs Market, by Type

• Octreotide • Lanreotide • Pasireotide

Global Somatostatin Analogs Market, Treatment

• Neuroendocrine Tumor (NET) • Carcinoid Syndrome • Acromegaly • Cushing’s Syndrome • Others

Global Somatostatin Analogs Market, By Region

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Key players operating in Global Somatostatin Analogs Market

• Novartis AG • Sun Pharmaceutical Industries Ltd • Midatech Pharma PLC • Ipsen Pharma • Chiasma, Inc. • Peptron, Inc. • Crinetics Pharmaceuticals • Dauntless Pharmaceuticals • Camurus AB • Teva Pharmaceuticals Inc. • Pfizer Inc • Fresenius Kabi

Table of Contents

Global Somatostatin Analogs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Somatostatin Analogs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Somatostatin Analogs Market Analysis and Forecast 6.1. Somatostatin Analogs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Somatostatin Analogs Market Analysis and Forecast, by Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Somatostatin Analogs Market Value Share Analysis, by Type 7.4. Somatostatin Analogs Market Size (US$ Bn) Forecast, by Type 7.5. Somatostatin Analogs Market Analysis, by Type 7.6. Somatostatin Analogs Market Attractiveness Analysis, by Type 8. Global Somatostatin Analogs Market Analysis and Forecast, By Treatment 8.1. Introduction and Definition 8.2. Key Findings 8.3. Somatostatin Analogs Market Value Share Analysis, By Treatment 8.4. Somatostatin Analogs Market Size (US$ Bn) Forecast, By Treatment 8.5. Somatostatin Analogs Market Analysis, By Treatment 8.6. Somatostatin Analogs Market Attractiveness Analysis, By Treatment 9. Global Somatostatin Analogs Market Analysis, by Region 9.1. Somatostatin Analogs Market Value Share Analysis, by Region 9.2. Somatostatin Analogs Market Size (US$ Bn) Forecast, by Region 9.3. Somatostatin Analogs Market Attractiveness Analysis, by Region 10. North America Somatostatin Analogs Market Analysis 10.1. Key Findings 10.2. North America Somatostatin Analogs Market Overview 10.3. North America Somatostatin Analogs Market Value Share Analysis, by Type 10.4. North America Somatostatin Analogs Market Forecast, by Type 10.4.1. Octreotide 10.4.2. Lanreotide 10.4.3. Pasireotide 10.4.4. Other 10.5. North America Somatostatin Analogs Market Value Share Analysis, By Treatment 10.6. North America Somatostatin Analogs Market Forecast, By Treatment 10.6.1. Neuroendocrine Tumor (NET) 10.6.2. Carcinoid Syndrome 10.6.3. Acromegaly 10.6.4. Cushing’s Syndrome 10.6.5. Others 10.7. North America Somatostatin Analogs Market Value Share Analysis, by Country 10.8. North America Somatostatin Analogs Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Somatostatin Analogs Market Analysis, by Country 10.10. U.S. Somatostatin Analogs Market Forecast, by Type 10.10.1. Octreotide 10.10.2. Lanreotide 10.10.3. Pasireotide 10.10.4. Others 10.11. U.S. Somatostatin Analogs Market Forecast, By Treatment 10.11.1. Neuroendocrine Tumor (NET) 10.11.2. Carcinoid Syndrome 10.11.3. Acromegaly 10.11.4. Cushing’s Syndrome 10.11.5. Other 10.12. Canada Somatostatin Analogs Market Forecast, by Type 10.12.1. Octreotide 10.12.2. Lanreotide 10.12.3. Pasireotide 10.12.4. Others 10.13. Canada Somatostatin Analogs Market Forecast, By Treatment 10.13.1. Neuroendocrine Tumor (NET) 10.13.2. Carcinoid Syndrome 10.13.3. Acromegaly 10.13.4. Cushing’s Syndrome 10.13.5. Other 10.14. North America Somatostatin Analogs Market Attractiveness Analysis 10.14.1. By Type 10.14.2. By Treatment 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Europe Somatostatin Analogs Market Analysis 11.1. Key Findings 11.2. Europe Somatostatin Analogs Market Overview 11.3. Europe Somatostatin Analogs Market Value Share Analysis, by Type 11.4. Europe Somatostatin Analogs Market Forecast, by Type 11.4.1. Octreotide 11.4.2. Lanreotide 11.4.3. Pasireotide 11.4.4. Others 11.5. Europe Somatostatin Analogs Market Value Share Analysis, By Treatment 11.6. Europe Somatostatin Analogs Market Forecast, By Treatment 11.6.1. Neuroendocrine Tumor (NET) 11.6.2. Carcinoid Syndrome 11.6.3. Acromegaly 11.6.4. Cushing’s Syndrome 11.6.5. Other 11.7. Europe Somatostatin Analogs Market Value Share Analysis, by Country 11.8. Europe Somatostatin Analogs Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Somatostatin Analogs Market Analysis, by Country 11.10. Germany Somatostatin Analogs Market Forecast, by Type 11.10.1. Octreotide 11.10.2. Lanreotide 11.10.3. Pasireotide 11.10.4. Others 11.11. Germany Somatostatin Analogs Market Forecast, By Treatment 11.11.1. Neuroendocrine Tumor (NET) 11.11.2. Carcinoid Syndrome 11.11.3. Acromegaly 11.11.4. Cushing’s Syndrome 11.11.5. Other 11.12. U.K. Somatostatin Analogs Market Forecast, by Type 11.12.1. Octreotide 11.12.2. Lanreotide 11.12.3. Pasireotide 11.12.4. Others 11.13. U.K. Somatostatin Analogs Market Forecast, By Treatment 11.13.1. Neuroendocrine Tumor (NET) 11.13.2. Carcinoid Syndrome 11.13.3. Acromegaly 11.13.4. Cushing’s Syndrome 11.13.5. Other 11.14. France Somatostatin Analogs Market Forecast, by Type 11.14.1. Octreotide 11.14.2. Lanreotide 11.14.3. Pasireotide 11.14.4. Others 11.15. France Somatostatin Analogs Market Forecast, By Treatment 11.15.1. Neuroendocrine Tumor (NET) 11.15.2. Carcinoid Syndrome 11.15.3. Acromegaly 11.15.4. Cushing’s Syndrome 11.15.5. Other 11.16. Italy Somatostatin Analogs Market Forecast, by Type 11.16.1. Octreotide 11.16.2. Lanreotide 11.16.3. Pasireotide 11.16.4. Others 11.17. Italy Somatostatin Analogs Market Forecast, By Treatment 11.17.1. Neuroendocrine Tumor (NET) 11.17.2. Carcinoid Syndrome 11.17.3. Acromegaly 11.17.4. Cushing’s Syndrome 11.17.5. Other 11.18. Spain Somatostatin Analogs Market Forecast, by Type 11.18.1. Octreotide 11.18.2. Lanreotide 11.18.3. Pasireotide 11.18.4. Others 11.19. Spain Somatostatin Analogs Market Forecast, By Treatment 11.19.1. Neuroendocrine Tumor (NET) 11.19.2. Carcinoid Syndrome 11.19.3. Acromegaly 11.19.4. Cushing’s Syndrome 11.19.5. Other 11.20. Rest of Europe Somatostatin Analogs Market Forecast, by Type 11.20.1. Octreotide 11.20.2. Lanreotide 11.20.3. Pasireotide 11.20.4. Others 11.21. Rest of Europe Somatostatin Analogs Market Forecast, By Treatment 11.21.1. Neuroendocrine Tumor (NET) 11.21.2. Carcinoid Syndrome 11.21.3. Acromegaly 11.21.4. Cushing’s Syndrome 11.21.5. Other 11.22. Europe Somatostatin Analogs Market Attractiveness Analysis 11.22.1. By Type 11.22.2. By Treatment 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Developments 12. Asia Pacific Somatostatin Analogs Market Analysis 12.1. Key Findings 12.2. Asia Pacific Somatostatin Analogs Market Overview 12.3. Asia Pacific Somatostatin Analogs Market Value Share Analysis, by Type 12.4. Asia Pacific Somatostatin Analogs Market Forecast, by Type 12.4.1. Octreotide 12.4.2. Lanreotide 12.4.3. Pasireotide 12.4.4. Others 12.5. Asia Pacific Somatostatin Analogs Market Value Share Analysis, By Treatment 12.6. Asia Pacific Somatostatin Analogs Market Forecast, By Treatment 12.6.1. Neuroendocrine Tumor (NET) 12.6.2. Carcinoid Syndrome 12.6.3. Acromegaly 12.6.4. Cushing’s Syndrome 12.6.5. Other 12.7. Asia Pacific Somatostatin Analogs Market Value Share Analysis, by Country 12.8. Asia Pacific Somatostatin Analogs Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Somatostatin Analogs Market Analysis, by Country 12.10. China Somatostatin Analogs Market Forecast, by Type 12.10.1. Octreotide 12.10.2. Lanreotide 12.10.3. Pasireotide 12.10.4. Others 12.11. China Somatostatin Analogs Market Forecast, By Treatment 12.11.1. Neuroendocrine Tumor (NET) 12.11.2. Carcinoid Syndrome 12.11.3. Acromegaly 12.11.4. Cushing’s Syndrome 12.11.5. Other 12.12. India Somatostatin Analogs Market Forecast, by Type 12.12.1. Octreotide 12.12.2. Lanreotide 12.12.3. Pasireotide 12.12.4. Others 12.13. India Somatostatin Analogs Market Forecast, By Treatment 12.13.1. Neuroendocrine Tumor (NET) 12.13.2. Carcinoid Syndrome 12.13.3. Acromegaly 12.13.4. Cushing’s Syndrome 12.13.5. Other 12.14. Japan Somatostatin Analogs Market Forecast, by Type 12.14.1. Octreotide 12.14.2. Lanreotide 12.14.3. Pasireotide 12.14.4. Others 12.15. Japan Somatostatin Analogs Market Forecast, By Treatment 12.15.1. Neuroendocrine Tumor (NET) 12.15.2. Carcinoid Syndrome 12.15.3. Acromegaly 12.15.4. Cushing’s Syndrome 12.15.5. Other 12.16. ASEAN Somatostatin Analogs Market Forecast, by Type 12.16.1. Octreotide 12.16.2. Lanreotide 12.16.3. Pasireotide 12.16.4. Others 12.17. ASEAN Somatostatin Analogs Market Forecast, By Treatment 12.17.1. Neuroendocrine Tumor (NET) 12.17.2. Carcinoid Syndrome 12.17.3. Acromegaly 12.17.4. Cushing’s Syndrome 12.17.5. Other 12.18. Rest of Asia Pacific Somatostatin Analogs Market Forecast, by Type 12.18.1. Octreotide 12.18.2. Lanreotide 12.18.3. Pasireotide 12.18.4. Others 12.19. Rest of Asia Pacific Somatostatin Analogs Market Forecast, By Treatment 12.19.1. Neuroendocrine Tumor (NET) 12.19.2. Carcinoid Syndrome 12.19.3. Acromegaly 12.19.4. Cushing’s Syndrome 12.19.5. Other 12.20. Asia Pacific Somatostatin Analogs Market Attractiveness Analysis 12.20.1. By Type 12.20.2. By Treatment 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Developments 13. Middle East & Africa Somatostatin Analogs Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Somatostatin Analogs Market Overview 13.3. Middle East & Africa Somatostatin Analogs Market Value Share Analysis, by Type 13.4. Middle East & Africa Somatostatin Analogs Market Forecast, by Type 13.4.1. Octreotide 13.4.2. Lanreotide 13.4.3. Pasireotide 13.4.4. Others 13.5. Middle East & Africa Somatostatin Analogs Market Value Share Analysis, By Treatment 13.6. Middle East & Africa Somatostatin Analogs Market Forecast, By Treatment 13.6.1. Neuroendocrine Tumor (NET) 13.6.2. Carcinoid Syndrome 13.6.3. Acromegaly 13.6.4. Cushing’s Syndrome 13.6.5. Other 13.7. Middle East & Africa Somatostatin Analogs Market Value Share Analysis, by Country 13.8. Middle East & Africa Somatostatin Analogs Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Somatostatin Analogs Market Analysis, by Country 13.10. GCC Somatostatin Analogs Market Forecast, by Type 13.10.1. Octreotide 13.10.2. Lanreotide 13.10.3. Pasireotide 13.10.4. Others 13.11. GCC Somatostatin Analogs Market Forecast, By Treatment 13.11.1. Neuroendocrine Tumor (NET) 13.11.2. Carcinoid Syndrome 13.11.3. Acromegaly 13.11.4. Cushing’s Syndrome 13.11.5. Other 13.12. South Africa Somatostatin Analogs Market Forecast, by Type 13.12.1. Octreotide 13.12.2. Lanreotide 13.12.3. Pasireotide 13.12.4. Others 13.13. South Africa Somatostatin Analogs Market Forecast, By Treatment 13.13.1. Neuroendocrine Tumor (NET) 13.13.2. Carcinoid Syndrome 13.13.3. Acromegaly 13.13.4. Cushing’s Syndrome 13.13.5. Other 13.14. Rest of Middle East & Africa Somatostatin Analogs Market Forecast, by Type 13.14.1. Octreotide 13.14.2. Lanreotide 13.14.3. Pasireotide 13.14.4. Others 13.15. Rest of Middle East & Africa Somatostatin Analogs Market Forecast, By Treatment 13.15.1. Neuroendocrine Tumor (NET) 13.15.2. Carcinoid Syndrome 13.15.3. Acromegaly 13.15.4. Cushing’s Syndrome 13.15.5. Other 13.16. Middle East & Africa Somatostatin Analogs Market Attractiveness Analysis 13.16.1. By Type 13.16.2. By Treatment 13.17. PEST Analysis 13.18. Key Trends 13.19. Key Developments 14. South America Somatostatin Analogs Market Analysis 14.1. Key Findings 14.2. South America Somatostatin Analogs Market Overview 14.3. South America Somatostatin Analogs Market Value Share Analysis, by Type 14.4. South America Somatostatin Analogs Market Forecast, by Type 14.4.1. Octreotide 14.4.2. Lanreotide 14.4.3. Pasireotide 14.4.4. Others 14.5. South America Somatostatin Analogs Market Value Share Analysis, By Treatment 14.6. South America Somatostatin Analogs Market Forecast, By Treatment 14.6.1. Neuroendocrine Tumor (NET) 14.6.2. Carcinoid Syndrome 14.6.3. Acromegaly 14.6.4. Cushing’s Syndrome 14.6.5. Other 14.7. South America Somatostatin Analogs Market Value Share Analysis, by Country 14.8. South America Somatostatin Analogs Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Somatostatin Analogs Market Analysis, by Country 14.10. Brazil Somatostatin Analogs Market Forecast, by Type 14.10.1. Octreotide 14.10.2. Lanreotide 14.10.3. Pasireotide 14.10.4. Others 14.11. Brazil Somatostatin Analogs Market Forecast, By Treatment 14.11.1. Neuroendocrine Tumor (NET) 14.11.2. Carcinoid Syndrome 14.11.3. Acromegaly 14.11.4. Cushing’s Syndrome 14.11.5. Other 14.12. Mexico Somatostatin Analogs Market Forecast, by Type 14.12.1. Octreotide 14.12.2. Lanreotide 14.12.3. Pasireotide 14.12.4. Others 14.13. Mexico Somatostatin Analogs Market Forecast, By Treatment 14.13.1. Neuroendocrine Tumor (NET) 14.13.2. Carcinoid Syndrome 14.13.3. Acromegaly 14.13.4. Cushing’s Syndrome 14.13.5. Other 14.14. Rest of South America Somatostatin Analogs Market Forecast, by Type 14.14.1. Octreotide 14.14.2. Lanreotide 14.14.3. Pasireotide 14.14.4. Others 14.15. Rest of South America Somatostatin Analogs Market Forecast, By Treatment 14.15.1. Neuroendocrine Tumor (NET) 14.15.2. Carcinoid Syndrome 14.15.3. Acromegaly 14.15.4. Cushing’s Syndrome 14.15.5. Other 14.16. South America Somatostatin Analogs Market Attractiveness Analysis 14.16.1. By Type 14.16.2. By Treatment 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Vehicles and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Vehicles 15.2.3.2. M&A Key Players, Forward Integration and Backward 15.2.3.3. Integration 15.3. Company Profiles: Key Players 15.3.1. Novartis AG 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Sun Pharmaceutical Industries Ltd 15.3.3. Midatech Pharma PLC 15.3.4. Ipsen Pharma 15.3.5. Chiasma, Inc. 15.3.6. Peptron, Inc 15.3.7. Crinetics Pharmaceuticals 15.3.8. Dauntless Pharmaceuticals 15.3.9. Camurus AB 15.3.10. Teva Pharmaceuticals Inc. 15.3.11. Pfizer Inc. 15.3.12. Fresenius Kabi 16. Primary Key Insights

About This Report

Report ID65664
Category Material & Chemical
Published DateJuly 2020
No of Pages193
Contact Us